Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.

Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.

Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Having initially targeted $115m in proceeds, the genome sequencing spinout of Stanford has closed its offering at $140m after a full exercise of the overallotment option.

Stanford's Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.

GSK-backed Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.

The gene therapy developer has boosted its initial public offering, which gave an exit to Alexandria Real Estate Equities, to more than $163m in size.

The SoftBank, Comcast and Alphabet-backed communication platform developer saw its shares pop and its market cap climb nearly 50% to $19.5bn following its direct listing.

The AbbVie Ventures-backed neurodegenerative disease treatment developer floated in the middle of its range having previously raised $129m in funding.